Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027

Go back to Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027
(NASDAQ: PPCB) Delayed: 0.28 +0.01 (3.70%)
Previous Close $0.27    52 Week High $ 
Open $0.28    52 Week Low $ 
Day High $0.28    P/E N/A 
Day Low $0.25    EPS $ 
Volume 46,944